Skip to content
DataLookout
Menu

NCT06743243

Effect of Tegoprazan for Elective Surgery Patients Under General Anesthesia

StatusEnrolling by Invitation
PhasePhase 4
Primary completion (estimated)

At risk: Primary completion moved 2 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 8 words
    • Primary completion pushed from Oct 30, 2026 to Dec 30, 2026
    • Secondary endpoints revised (3)
    • Collaborators: details revised at 1 of 4 entries
  2. Notable Lead sponsor: Kim, Young Sung to Seok Kyeong Ohv2 Show 6 more changesShow less
    • Trial status: Not Yet Recruiting to Enrolling by Invitation
    • Start date changed from estimate of Mar 2025 to Jul 23, 2025
    • Primary completion date: Oct 2026 to Oct 30, 2026
    • Study completion date: Oct 2026 to Dec 30, 2026
    • Site contact updated
    • Collaborators revised (4)
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Gastric pH right after endotracheal intubation
Timeframe: right after endotracheal intubation

Secondary (3)

Change of oral, esophageal and gastric pH
Gastric volume evaluated by Ultrasound
Risk of aspiration(pH < 2.5, Gastric volume > 0.4mL/kg) and frequency of complications(aspiration etc.)

Arms and interventions

Group TExperimental

Tegoprazan OD tab. 50 mg PO + Saline 20 ml IV, one hour before general anesthesia.

Group FActive comparator

Famotidine 20 mg/10 ml + Saline 10 ml IV + Tegoprazan OD tab. 50 mg placebo PO, one hour before general anesthesia.

Group CPlacebo comparator

Tegoprazan OD tab. 50 mg placebo PO + Saline 20 ml IV, one hour before general anesthesia.

Drugs: Tegoprazan, Famotidine, Placebo

Sites

1 site in 1 country

  • Korea University Medical Center, Guro HospitalSeoul, South Korea